Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glembatumumab vedotin in high risk triple negative breast cancer
NCT03473691Phase 1Withdrawn
- Sponsor
- University of Virginia
- Start
- May 2018
- Primary completion
- May 2018
01
Overview
Phase 1, open-label, single-arm trial of glembatumumab vedotin in triple-negative breast cancer (TNBC), sponsored by University of Virginia. Primary endpoints: Incidence of Adverse Events, Proportion of patients who complete 4 cycles of GV within 15 weeks and 1 more. Planned start May 2018; status: withdrawn.
02
Drugs
glembatumumab vedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03473691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473691.